@article{a6e02445ec004de8a9f429086c5fbbac,
title = "Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development",
abstract = "We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the patterns of genomic alterations in human glioblastoma (GBM), identifying frequent p18INK4C and p16INK4A codeletion. Functional reconstitution of p18INK4C in GBM cells null for both p16INK4A and p18INK4C resulted in impaired cell-cycle progression and tumorigenic potential. Conversely, RNAi-mediated depletion of p18INK4C in p16INK4A-deficient primary astrocytes or established GBM cells enhanced tumorigenicity in vitro and in vivo. Furthermore, acute suppression of p16INK4A in primary astrocytes induced a concomitant increase in p18INK4C. Together, these findings uncover a feedback regulatory circuit in the astrocytic lineage and demonstrate a bona fide tumor suppressor role for p18INK4C in human GBM wherein it functions cooperatively with other INK4 family members to constrain inappropriate proliferation.",
keywords = "CELLCYCLE",
author = "Ruprecht Wiedemeyer and Cameron Brennan and Heffernan, {Timothy P.} and Yonghong Xiao and John Mahoney and Alexei Protopopov and Hongwu Zheng and Graham Bignell and Frank Furnari and Cavenee, {Webster K.} and Hahn, {William C.} and Koichi Ichimura and Collins, {V. Peter} and Chu, {Gerald C.} and Stratton, {Michael R.} and Ligon, {Keith L.} and Futreal, {P. Andrew} and Lynda Chin",
note = "Funding Information: We thank Dr. Ron DePinho for critical reading of the manuscript, Dr. Christoph Geisen for the INK4A cDNA and the E2F expression vectors, Dr. Yue Xiong for the INK4C cDNA, and Thomas Santarius and Steven N. Quayle. Cell line resequencing was performed by the Cancer Genome Project at the Wellcome Trust Sanger Institute, UK. The genomic data were generated in the Center for Applied Cancer Science of the Belfer Institute for Innovative Cancer Science at Dana-Farber Cancer Institute. R.W. is funded by a Mildred-Scheel fellowship (Deutsche Krebshilfe). ShRNA were provided from the RNAi Consortium at the Broad Institute. T.P.H. is funded by NIH T32 AR007098. P.A.F and M.R.S are funded by the Wellcome Trust. W.K.C. is a Fellow of the National Foundation for Cancer Research. This work is supported in part by NIH grants RO1CA99041 (L.C.) and P01CA95616 (W.K.C., F.F., W.C.H., K.L.L., C.B., and L.C.), as well as awards from Accelerate Brain Cancer Cure (to C.B.), the Goldhirsh Foundation (to F.F. and L.C.), and the Chris Elliot Foundation (to L.C.). ",
year = "2008",
month = apr,
day = "8",
doi = "10.1016/j.ccr.2008.02.010",
language = "English (US)",
volume = "13",
pages = "355--364",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}